OncoOne Targets Cancer-Related Isoform, OxMIF, In Multiple Ways
Lead Compound Could Be Clinic-Ready By 2022
Emerging Company Profile: Austria’s OncoOne could have an anticancer biologic which targets oxidized macrophage migration inhibitor factor ready for the clinic in around two years.
You may also be interested in...
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The coronavirus pandemic held back sales of Lundbeck’s newest product, Vyepti, in the US during the first half, but the company spent less than expected on SG&A because of COVID-19, and increased investments in marketing infrastructure and restructuring R&D.